Related Experiment Video

Updated: Aug 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Management of Hepatitis C in HIV-infected Patients

Benigno Rodriguez1, David A Bobak

  • 1Division of Infectious Diseases, University Hospitals of Cleveland, 2061 Cornell Road, Suite 401, Cleveland, OH 44106, USA. rodriguez.benigno@clevelandactu.org.

Current Infectious Disease Reports
|February 25, 2005
PubMed

Insights

Hepatitis C virus (HCV) coinfection significantly impacts HIV patients, accelerating liver disease. Current treatments are suboptimal, prompting research into new therapies targeting novel molecular pathways.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Immunology

Background:

  • HIV survival has increased due to antiretroviral therapy.
  • Hepatitis C virus (HCV) coinfection is a major cause of illness and death in HIV patients.
  • HCV/HIV coinfection worsens liver disease and may affect HIV progression.

Purpose of the Study:

  • To review the impact of HCV coinfection in HIV patients.
  • To outline current management and antiviral treatment strategies.
  • To discuss emerging therapies for HCV/HIV coinfection.

Main Methods:

  • Review of major clinical trials for HCV treatment in coinfected patients.
  • Analysis of current treatment guidelines and emerging therapeutic agents.
  • Discussion of novel molecular targets for antiviral therapy.

Main Results:

  • Pegylated interferon-alpha and ribavirin is the current standard of care for HCV/HIV coinfection.
  • This regimen's effectiveness and tolerability are suboptimal, especially for genotype 1 HCV.
  • Newer agents targeting novel molecular pathways are under development.

Conclusions:

  • HCV coinfection poses significant challenges for HIV-infected individuals.
  • Current treatment regimens require improvement for better outcomes.
  • Emerging therapies offer promise for more effective management of HCV/HIV coinfection.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...